### Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 4

#### CARACO PHARMACEUTICAL LABORATORIES LTD

Form 4

December 03, 2004

EODM 4							OMB APPROVAL			
FORM 4	OMB Number:	3235-0287								
Check this box if no longer	Washington, D.C. 20549  STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF						January 31, 2005			
subject to Section 16. Form 4 or			ECUR	Estimated burden hou	ırs per					
Form 4 or Form 5 obligations may continue.  See Instruction 1(b).  Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Respon	ses)									
1. Name and Address JOLIAT JAY F	of Reporting Person *	2. Issuer Na Symbol	2. Issuer Name <b>and</b> Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer				
	CARACO PHARMACEUTICAL LABORATORIES LTD [CPD]				neck all applicable)					
(Last) (I				(Month/Day/Year)			_X Director 10% Owner Officer (give title Other (specify			
36801 WOODW <i>a</i> 301	12/03/2004	4		below)	below)					
(S		4. If Amendment, Date Original Filed(Month/Day/Year)			<ul><li>6. Individual or Joint/Group Filing(Check</li><li>Applicable Line)</li><li>_X_ Form filed by One Reporting Person</li></ul>					
BIRMINGHAM,	MI 48009				Form filed by I Person	More than One R	eporting			
(City) (S	State) (Zip)	Table I	- Non-L	Derivative Securities A	acquired, Disposed o	f, or Beneficia	lly Owned			
1.Title of Security (Month/Day/Year) 2. Transaction Date 2A. Deemed Execution Date, if any (Month/Day/Year)		on Date, if Tra	ansaction de	4. Securities nAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Securities I Beneficially ( Owned (	6. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Reported

Transaction(s)

(Instr. 3 and 4)

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5.	6. Date Exercisable and	7. Title and	8. Price of	9. Nı
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionNumber	Expiration Date	Amount of	Derivative	Deri

(A)

or

Code V Amount (D) Price

### Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Month/Day/Year)	Code (Instr. 8)			Underlying Securities (Instr. 3 and 4)	Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr	
			Code V	(Instr. 3, 4, and 5)		Expiration Date	Title Amount or Number		,,
							of Shares		

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
r g	Director	10% Owner	Officer	Other		
JOLIAT JAY F 36801 WOODWARD AVE SUITE 301 BIRMINGHAM, MI 48009	X					

## **Signatures**

/s/ Jennifer Evans, Power of 12/03/2004 Attorney \*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

### **Remarks:**

Jay F. Joliat is no longer subject to File Form 4, pursuant to Section 16 requirements.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2